Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | IL6ST | P40189 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058895 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL5058893 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL3963007 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL8863773 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL14175205 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL3963002 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747719 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747720 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747717 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL14175204 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292101-B1 | TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107709295-B | Tricyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-08 | — | — | US | disclosed |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3292101-A1 | TRICYCLIC SULFONES AS ROR MODULATORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2016179460-A1 | TRICYCLIC SULFONES AS RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-10 | — | — | US | disclosed |
| EP-2734515-B1 | THIOPHEN-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| EP-2773615-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| US-8741946-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2734515-A1 | THIOPHEN-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013064543-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| US-20130052161-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2013010112-A1 | THIOPHEN-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | NAAA 3889/4885ABCB1 1849/4885FAAH 1621/4885 |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | NAAA 4009/4885ABCB1 1802/4885FAAH 1538/4885 |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | RORB, RORC, RORA | NAAA 3516/4885ABCB1 1815/4885FAAH 1312/4885 |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | NAAA 3889/4885ABCB1 1849/4885FAAH 1621/4885 |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | NAAA 4009/4885ABCB1 1802/4885FAAH 1538/4885 |
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | SCN2A, SCN1A, ORAI2 | NAAA 1958/4885ABCB1 2612/4885FAAH 2507/4885 |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | NR1H4, HAVCR2, NR1H3 | NAAA 3926/4885ABCB1 324/4885FAAH 3271/4885 |
| US-20130052161-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NAAA 2224/4885ABCB1 167/4885FAAH 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.